ArticleJournal of thoracic disease2025
Hereditary hemorrhagic telangiectasia with pulmonary hypertension: a report of three cases.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics of pulmonary hypertension associated with hereditary hemorrhagic telangiectasia treated with bevacizumab: a single-center case series.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder characterized by multisystem vascular malformations, with a low prevalence worldwide. Pulmonary hypertension (PH), a grave complication of HHT, is associated with a poor prognosis. At present, an agreed approach to the management of HHT in patients with PH is not available. The report herein details the diagnostic and therapeutic processes of three patients with HHT complicated by PH, with the aim of providing clinical insights for practitioners. Case Description: The following report details three cases of HHT with PH. All three patients had a history of recurrent epistaxis, as well as dilated blood vessels in the skin and mucous membranes. Consequently, all patients underwent right heart catheterisation (RHC), a procedure that confirmed the diagnosis of PH in all cases. Following diagnosis, Case 1 received treatment consisting of bevacizumab in conjunction with tadalafil and macitentan, Case 2 was treated with thalidomide in combination with sildenafil and macitentan, and Case 3 received a combination of sildenafil and ambrisentan. A family history of disease was identified in all three cases, with Case 1 and Case 2 exhibiting a family history of mutations in the Conclusions: The combination of HHT and PH is associated with a poor prognosis and limited treatment options. For patients who do not respond well to targeted drug therapy, the administration of antiangiogenic drugs in combination is recommended. It is imperative for healthcare professionals to exercise heightened suspicion of the diagnosis in patients with PH and telangiectasia of the skin and mucous membranes, and to undertake a comprehensive investigation into the family history. The implementation of genetic testing is crucial to mitigate the occurrence of missed diagnoses and misdiagnoses of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.